Disclosed is an IgG Fc fragment useful as a drug carrier. A recombinant vector expressing the IgG Fc fragment, a transformant transformed with the recombinant vector, and a method of preparing an IgG Fc fragment are disclosed. When conjugated to a certain drug, the IgG Fc fragment improves the in vivo duration of action of the drug and minimizes the in vivo activity reduction of the drug.

Described are immunoglobulins provided with a toxic moiety, comprising at least an immunoglobulin variable region that specifically binds to an MHC-peptide complex preferentially associated with aberrant cells. These immunoglobulins provided with a toxic moiety may be used in selectively modulating biological processes. These immunoglobulins provided with a toxic moiety are of particular use in pharmaceutical compositions for the treatment of diseases related to cellular aberrations, such as cancers and autoimmune diseases.

The invention relates to IL-21, to antibodies and related fragments thereof for binding to IL-21, to production of said antibodies and fragments and to use of said antibodies and fragments for detection and therapy of various conditions, in particular inflammation, infection and oncology.

The present invention relates to ligand-binding molecules containing a single-domain antibody in which the binding activity to the ligand is attenuated by the cleavage of a cleavage site, methods for producing the same, complexes formed by the ligand-binding molecules and ligands, fusion proteins comprising the ligand-binding molecules and ligands, and pharmaceutical compositions comprising the ligand-binding molecules or fusion proteins of the ligand-binding molecules and ligands.

The present invention includes composition and methods for treating a patient with a known or suspected viral-induced infection, respiratory disorder or exacerbation thereof, or preventing the same, the method comprising: administering to the patient in need thereof a therapeutically effective amount of an agent, wherein the agent comprises at least one of: (a) an activatable pro-IFN-Fc antibody, (b) an anti-viral-associated antibody or anti-epithelial-associated antibody (aVab/aEab)-IFN-Fc fusion protein, wherein the aVab/aEab is an anti-PD-L1, anti-VEGF, or anti-EGFR antibody variable domain, an activatable pro-aVab/aEab-IFN-Fc, an activatable aVab/aEab-pro-IFN-Fc, or pro-aVab/aEab-pro-IFN-Fc; wherein the fusion antibody prodrugs are activatable by proteases upregulated in upper and lower respiratory tracts during viral infection; wherein the preferred route of administration is via nasopharyngeal or oropharyngeal airways, and wherein the administration results in suppression of viral replication causing a reduction in the viral-induced infection, respiratory disorder or exacerbation thereof in the patient.

Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.

Provided is an anti-human transferrin receptor antibody or an analog thereof, wherein in the heavy chain variable region of the antibody, (a) CDR1 comprises the amino acid sequence set forth as SEQ ID NO: 62 or SEQ ID NO: 63, (b) CDR2 comprises the amino acid sequence set forth as SEQ ID NO: 13 or SEQ ID NO: 14, and (c) CDR3 comprises the amino acid sequence set forth as SEQ ID NO: 15 or SEQ ID NO: 16, and an analogue thereof.

This disclosure relates to a modified α-helical bundle cytokine, with reduced activity via an α-helical bundle cytokine receptor, wherein the α-helical bundle cytokine is specifically delivered to target cells. Preferably, the α-helical bundle cytokine is a mutant, more preferably it is a mutant interferon, with low affinity to the interferon receptor, wherein the mutant interferon is specifically delivered to target cells. The targeting is realized by fusion of the modified α-helical bundle cytokine to a targeting moiety, preferably an antibody. This disclosure relates further to the use of such targeted modified α-helical bundle cytokine to treat diseases. A preferred embodiment is the use of a targeted mutant interferon, to treat diseases, preferably viral diseases and tumors.

The application relates to a fusion protein comprising an antibody molecule, or antigen-binding fragment thereof, and a member of the vascular endothelial growth factor family, such as VEGF-C or VEGF-D. The antibody molecule preferably binds an antigen associated with angiogenesis, such as the ED-A isoform of fibronectin. In particular, the application relates to the therapeutic use of such fusion protein in the treatment of an inflammatory disease or disorder.

The present invention provides, among other things, methods of treating post-cardiac injury syndrome (PCIS) or pericarditis, comprising a step of administering to a subject in need of treatment an interleukin-1 receptor-Fc fusion protein at a therapeutically effective dose and an administration interval for a treatment period sufficient to improve, stabilize or reduce one or more signs and symptoms of pericarditis relative to a control.